|Francisco Negron, Patheon vice president|
Patheon plans to add 488 jobs over the next 5 years at its Greenville, NC, facility, and could eventually bring in more than $6.3 million in incentives offered by the state under a job development program. It is all part of the plans by the Durham, NC-based contract manufacturer to invest $159 million to expand and modernize the plant.
If Patheon, whose parent is DPx, fulfills its pledge to add all the jobs by 2019, the incentives would be paid out under North Carolina's Job Development Investment Grant program, Gov. Pat McCrory's office said in a press release. More than 1,000 employees already work at the facility.
"We appreciate the support and collaboration of the Governor's office and the Greenville Chamber of Commerce to establish a world-class operation in Greenville," Franco Negron, a Patheon vice president, said in a statement.
DPx was created earlier this year by the $2.6 billion merger of Patheon and Netherlands-based DSM Pharmaceutical Products. DPx is 51% owned by private investment group JLL Partners and 49% by Royal DSM.
The Greenville project is the second capacity expansion announced by DPx in the past two months. In August, the company agreed to buy Gallus BioPharmaceuticals for an undisclosed sum, picking up its first two biologics plants in the U.S., one in St. Louis, MO, and one in Princeton, NJ. They will be folded into Patheon's biologics group, which has existing sites in Groningen, the Netherlands, and Brisbane, Australia.
- see the release